In a strange twist, the newest retail store from Nordstrom will carry no inventory. Instead, the company hopes a unique menu of services will provide a rich enough experience to connect with shoppers – a trend that is growing quickly in the brick-and-mortar world. The cast also looks at how Starbucks is faring under the new leadership of Kevin Johnson.

It’s not always an easy decision, and in most cases you should do some planning first, but there are times when you’re doing the right thing in quitting your job.  Of course there’s a difference between wanting to quit and needing to quit and some things you should do before giving notice.

The streaming service is planning to go public soon and we have our hands on their filing with the SEC! We run through the company's books, talk about the streaming space, and take a look at the company's long-term prospects.

Energy Secretary Rick Perry announced the Department of Energy is releasing 500,000 barrels of oil from the Strategic Petroleum Reserves. We discuss the impact and importance of the move.

Promo: Big-cap biopharma could come knocking if Juno Therapeutics’ next-generation CAR-T is safer than its competitors, and Medtronic's already investing billions in Mazor Robotics, a maker of surgical robots. Sponsored link: http://www.casper.com/fool Code: fool.

Amazon has already begun to weaponize its Whole Foods stores, and we look at how competing retailers like Kroger and Costco are feeling the pressure. Meanwhile, the major dollar store chains are facing their own challenges from larger retail rivals.

Thanks to Casper for supporting the podcast. Save $50 on a mattress at http://www.casper.com/fool, code “fool”.

IF brings you stories and coverage of different sectors of the stock market every day, but what trends are the hosts most excited about, and what stocks are on their watch lists? We bring everyone into the studio for this bonus episode to answer these questions and introduce the new Thursday host Sarah Priestley.

We toss around some terms week-to-week and don't always do the best job explaining them in-depth. Today, we dust off our college accounting books to talk about the difference between capitalizing and expensing a purchase, what deferred revenue is, and why operating leverage is a beautiful thing.

In the ongoing devastation of Hurricane Harvey headlines are surfacing about the storms impact on US oil and Gas -- on this episode we discuss potential outcomes for the industry, and touch on the recent appointment of a new CEO for GE.
 

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion. 

Join us for a look at the incredible growth of e-sports and the opportunity it presents to various industry stakeholders, including game publishers, content networks, and the players themselves. We also discuss the recent legal troubles at iRobot.

Two years ago we tossed out a terrible ballpark on the revenue Apple Music might be able to bring in for the tech giant. Today we talk about that mistake and how to set yourself up to make better projections.

Thanks to Harry’s for supporting Industry Focus. Get your free trial set – go to Harrys.com/fool

Everyone makes mistakes, the important thing is to learn from them.

We said what? Let’s face it, sometimes our predictions miss the mark, and with Rite Aid and Opko Health, they missed the mark by a lot. Here’s what we said, why we said it, and what we learned from our mistakes.

We said what?!? That is our theme for Industry Focus this week, and we continue the discussion with missed calls on Wal-Mart’s Jet.com acquisition and the 2,000 stores Amazon was supposed to open in the next several years.

Thanks to Harry’s for supporting the Motley Fool. Get your Free Trial Set -- go to Harrys.com/fool.

Everyone makes mistakes. But not many of us air them publicly. That's the theme of this week's Industry Focus, starting with our prediction in 2015 that concerns about Wells Fargo's cross-selling culture were much ado about nothing.

We run through recent wearables market data from Strategy Analytics, check in on the major players, and talk about the long-term outlook for Fitbit.

A solar eclipse occurs Monday -- what that means for solar producers may surprise you.

With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.

For several years, Procter & Gamble has been spinning off low-priority brands and cutting costs to streamline its business. But with little to show for those efforts, billionaire Nelson Peltz wants a seat at the table. Meanwhile, a slow summer blockbuster season is taking a major toll on theater operators.

Business development companies are undergoing a sea change as the asset class becomes more institutionalized.

Snap's quarterly update was... uninspiring. On this show, we talk about the updated user counts, ask some questions on engagement metrics, and run through the new financials.

Fracking has been the oil industry buzzword for years, here’s what the process actually means.

Scotts Miracle Gro could be the best marijuana stock to buy, while Illumina could be the best bet to capitalize on DNA-based medicine.